Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.52 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945279 | 1.00 | TBXAS1 (0.52) | TBXAS1EGLN3KDM4EALDH1A1PRKCI | |
| SCHEMBL3310813 | 1.00 | TBXAS1 (0.52) | TBXAS1EGLN3KDM4EALDH1A1PRKCI | |
| SCHEMBL13635784 | 0.89 | TBXAS1 (0.56) | TBXAS1EGLN3KDM4EALDH1A1PRKCI | |
| SCHEMBL13639840 | 0.82 | TBXAS1 (0.52) | TBXAS1EGLN3KDM4EALDH1A1PRKCI | |
| SCHEMBL2947596 | 0.80 | TBXAS1 (0.51) | TBXAS1EGLN3KDM4EALDH1A1QPCT | |
| SCHEMBL10646269 | 0.80 | TBXAS1 (0.51) | TBXAS1EGLN3KDM4EALDH1A1QPCT | |
| SCHEMBL2947594 | 0.80 | TBXAS1 (0.51) | TBXAS1EGLN3KDM4EALDH1A1QPCT | |
| SCHEMBL28726885 | 0.78 | — | — | |
| SCHEMBL4429215 | 0.77 | TBXAS1 (0.60) | TBXAS1EGLN3ALDH1A1PRKCI | |
| SCHEMBL11201930 | 0.77 | TBXAS1 (0.55) | TBXAS1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | TBXAS1 406/4885EGLN3 2068/4885KDM4E 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.